{"id":"vp16-atg","safety":{"commonSideEffects":[{"rate":"20-40%","effect":"Myelosuppression"},{"rate":"10-30%","effect":"Nausea and vomiting"},{"rate":"10-20%","effect":"Fatigue"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"VP16, also known as etoposide, is a topoisomerase II inhibitor that induces DNA damage by forming a stable cleavage complex, which leads to DNA strand breaks and ultimately cell death. This mechanism is particularly effective in rapidly dividing cancer cells.","oneSentence":"VP16 is an alkylating agent that works by cross-linking DNA, thereby inhibiting DNA replication and transcription.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:40:53.239Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Small cell lung cancer"},{"name":"Testicular cancer"},{"name":"Ovarian cancer"}]},"trialDetails":[{"nctId":"NCT00716066","phase":"PHASE2","title":"Autologous Stem Cell Transplant for Neurologic Autoimmune Diseases","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2008-06","conditions":"Autoimmune Disease, Neurologic Autoimmune Disease, Autologous Transplant Autoimmune","enrollment":53},{"nctId":"NCT04047628","phase":"PHASE3","title":"Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2019-12-19","conditions":"Relapsing Multiple Sclerosis, Relapsing Remitting Multiple Sclerosis, Secondary Progressive Multiple Sclerosis","enrollment":156},{"nctId":"NCT04425070","phase":"PHASE1, PHASE2","title":"A Study of Evaluating the Safety and Efficacy of ATG-010 Combined With Chemotherapy Sequential With ATG-010 Monotherapy Maintenance in Peripheral T- and NK/T-cell Lymphoma","status":"TERMINATED","sponsor":"Antengene Corporation","startDate":"2020-08-18","conditions":"Peripheral T-cell Lymphoma, NK/T-cell Lymphoma","enrollment":56},{"nctId":"NCT07059156","phase":"PHASE2, PHASE3","title":"Multicenter Study of Combined Chemotherapy and Transplantation for Adult ALL","status":"RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-06-01","conditions":"Acute Lymphoblastic Leukemia, Adult","enrollment":50},{"nctId":"NCT04530487","phase":"PHASE2","title":"Donor Stem Cell Transplant After Chemotherapy for the Treatment of Recurrent or Refractory High-Risk Solid Tumors in Pediatric and Adolescent-Young Adults","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2020-08-19","conditions":"Desmoplastic Small Round Cell Tumor, Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor, Recurrent Desmoplastic Small Round Cell Tumor","enrollment":1},{"nctId":"NCT06741813","phase":"NA","title":"Allo-HSCT vs ASCT in Adult T-LBL","status":"NOT_YET_RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2025-01-01","conditions":"T Lymphoblastic Lymphoma","enrollment":230},{"nctId":"NCT04521946","phase":"PHASE1","title":"Chemotherapy and Donor Stem Transplant for the Treatment of Patients With High Grade Brain Cancer","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-01-14","conditions":"Anaplastic Ependymoma, Atypical Teratoid/Rhabdoid Tumor, Central Nervous System Germ Cell Tumor","enrollment":""},{"nctId":"NCT01949129","phase":"PHASE2, PHASE3","title":"Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia","status":"RECRUITING","sponsor":"St. Anna Kinderkrebsforschung","startDate":"2013-04","conditions":"Acute Lymphoblastic Leukaemia","enrollment":1800},{"nctId":"NCT05029206","phase":"","title":"Hematopoietic Stem Cell Transplantation for Treatment of Multiple Sclerosis in Sweden","status":"COMPLETED","sponsor":"Uppsala University","startDate":"2021-05-05","conditions":"Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting","enrollment":174},{"nctId":"NCT00003816","phase":"PHASE2, PHASE3","title":"Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer","status":"COMPLETED","sponsor":"Roswell Park Cancer Institute","startDate":"1998-10-19","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Lymphoma","enrollment":361},{"nctId":"NCT01104025","phase":"PHASE2","title":"Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2010-04","conditions":"Hemophagocytic Lymphohistiocytosis","enrollment":31},{"nctId":"NCT00439556","phase":"PHASE2","title":"Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2007-02-13","conditions":"CD20 Positive, Hematopoietic and Lymphoid Cell Neoplasm, Lymphocytic Neoplasm","enrollment":40},{"nctId":"NCT00550992","phase":"NA","title":"Different Therapies in Treating Infants With Newly Diagnosed Acute Leukemia","status":"UNKNOWN","sponsor":"Dutch Childhood Oncology Group","startDate":"2006-01","conditions":"Leukemia","enrollment":445},{"nctId":"NCT00482053","phase":"PHASE2","title":"Phase 2 Poor Risk DLBCL of TLI and ATG Followed by Matched Allogeneic HT as Consolidation to Autologous HCT","status":"TERMINATED","sponsor":"Stanford University","startDate":"2006-10","conditions":"Lymphoma, B-cell, Lymphoma, Non-Hodgkin, Diffuse Large B-cell Lymphoma (DLBCL)","enrollment":3},{"nctId":"NCT00481832","phase":"PHASE2","title":"Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma","status":"TERMINATED","sponsor":"Stanford University","startDate":"2007-01","conditions":"Lymphoma, Non-Hodgkin","enrollment":50},{"nctId":"NCT00281879","phase":"PHASE2","title":"Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2006-02","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Lymphoma","enrollment":200},{"nctId":"NCT00288626","phase":"PHASE2","title":"High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis (HALT MS) Study","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2006-07","conditions":"Relapsing-Remitting Multiple Sclerosis","enrollment":25},{"nctId":"NCT00691015","phase":"PHASE2","title":"Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplant","status":"COMPLETED","sponsor":"Barbara Ann Karmanos Cancer Institute","startDate":"2008-05","conditions":"Chronic Myeloproliferative Disorders, Leukemia, Lymphoma","enrollment":48},{"nctId":"NCT00914849","phase":"PHASE2","title":"Intravenous (IV) AMD3100 for Mobilization and Matched Related Transplant for Advanced Hematological Malignancies","status":"COMPLETED","sponsor":"Washington University School of Medicine","startDate":"2009-08","conditions":"Hematologic Neoplasms","enrollment":68},{"nctId":"NCT00317408","phase":"NA","title":"Combination Chemotherapy Followed By Stem Cell Transplant in Treating Young Patients With Progressive or Relapsed Anaplastic Large Cell Lymphoma","status":"UNKNOWN","sponsor":"European Inter-group Cooperation on Childhood and Adolescent Non Hodgkin Lymphoma","startDate":"2004-04","conditions":"Lymphoma","enrollment":96},{"nctId":"NCT01423747","phase":"PHASE3","title":"Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia","status":"UNKNOWN","sponsor":"St. Anna Kinderkrebsforschung","startDate":"2003-07","conditions":"Lymphoblastic Leukemia, Acute, Childhood;","enrollment":400},{"nctId":"NCT01423500","phase":"PHASE3","title":"ALL-SCT BFM International- HSCT in Children and Adolescents With ALL","status":"UNKNOWN","sponsor":"St. Anna Kinderkrebsforschung","startDate":"2007-01","conditions":"Lymphoblastic Leukemia, Acute, Childhood;","enrollment":405},{"nctId":"NCT00682305","phase":"PHASE2","title":"Allogeneic Stem Cell Transplantation (SCT) With Treosulfan, VP-16 and Cyclophosphamid for Patients With Acute Lymphoblastic Leukemia (ALL)","status":"COMPLETED","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2007-03","conditions":"Acute Lymphoblastic Leukemia","enrollment":50},{"nctId":"NCT02290132","phase":"","title":"ATG Could Improve the Outcome Of Hematopoietic Stem Cell Transplant in Patients With Highly Aggressive T Cell Tumors","status":"UNKNOWN","sponsor":"Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine","startDate":"2013-08","conditions":"Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma","enrollment":63},{"nctId":"NCT00589563","phase":"PHASE2","title":"Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer","status":"COMPLETED","sponsor":"City of Hope Medical Center","startDate":"2007-05","conditions":"Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Infection","enrollment":32},{"nctId":"NCT00334672","phase":"PHASE3","title":"Combination Chemotherapy Followed By Donor Stem Cell Transplant in Treating Patients With Hemophagocytic Lymphohistiocytosis","status":"UNKNOWN","sponsor":"Children's Cancer and Leukaemia Group","startDate":"2006-03","conditions":"Nonneoplastic Condition","enrollment":288},{"nctId":"NCT00304018","phase":"PHASE1","title":"Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2002-10","conditions":"Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm","enrollment":5},{"nctId":"NCT00972101","phase":"PHASE1","title":"Infusion of Expanded Cord Blood T Cells","status":"WITHDRAWN","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-09","conditions":"Stem Cell Transplantation, Leukemia, Lymphoma","enrollment":""},{"nctId":"NCT00004904","phase":"PHASE1","title":"Stem Cell Transplantation in Treating Patients With Hematologic Cancer","status":"COMPLETED","sponsor":"Northwestern University","startDate":"1999-10","conditions":"Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia","enrollment":""},{"nctId":"NCT00006054","phase":"NA","title":"Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies","status":"TERMINATED","sponsor":"Fairview University Medical Center","startDate":"2000-03","conditions":"Immunologic Deficiency Syndromes, Chediak-Higashi Syndrome, Common Variable Immunodeficiency","enrollment":""},{"nctId":"NCT00006056","phase":"NA","title":"Pilot Study of Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients With Life Threatening Hemophagocytic Disorders","status":"UNKNOWN","sponsor":"Fairview University Medical Center","startDate":"2000-03","conditions":"Chediak-Higashi Syndrome, Graft Versus Host Disease, X-Linked Lymphoproliferative Syndrome","enrollment":40}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":18,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Etoposid, Antithymoglobuline","VP16: Etoposid","ATG: Antithymoglobuline"],"phase":"phase_3","status":"active","brandName":"VP16, ATG","genericName":"VP16, ATG","companyName":"St. Anna Kinderkrebsforschung","companyId":"st-anna-kinderkrebsforschung","modality":"Small molecule","firstApprovalDate":"","aiSummary":"VP16 is not mentioned in the provided facts, but based on the information, ATG (anti-thymocyte globulin) is used in the treatment of various immunologic deficiency syndromes, including Chediak-Higashi Syndrome, Common Variable Immunodeficiency, Graft Versus Host Disease, and X-Linked Lymphoproliferative Syndrome. ATG is administered as part of an allogeneic bone marrow transplantation regimen, which also includes busulfan and cyclophosphamide.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}